Navigation Links
Kiwa Fertilizers Pass Independent Tests
Date:1/7/2008

BEIJING and CLAREMONT, Calif., Jan. 7 /Xinhua-PRNewswire-FirstCall/ -- Kiwa Bio-Tech Products Group Corporation (KWBT.OB) announced that: Xinjiang Corps Agro-technology Extended Terminal promulgated the test results on Kiwa's fertilizer products "Pen Duo Shou" and "Jin Peng Jia Bao", both of which passed fertilizer sample tests. The new official fertilizer certificate replaces the previous Temporary Amino Acid Leaf Fertilizer Registration Certificate.

In 2007, Xinjiang Corps Agro-technology Extended Terminal arranged tests on processing tomato and cotton with Kiwa fertilizer products "Pen Duo Shou" and "Jin Peng Jia Bao". The recent test results of these two fertilizer products show that:

-- Pen Duo Shou can increase the number of tomato fruits per plant as

well as the net weight of single tomatoes and thereby provides a

better yield.

-- Jin Peng Jia Bao can increase the number of cotton balls on individual

plants as well as the net weight of every individual cotton ball

therefore increase crop yield of cotton.

-- These independent tests prove that these two new Kiwa fertilizer

products have the positive effect of increasing crop production meet

the objective of creating a high economic benefit.

In addition, the two products passed the sample tests and were approved by China Fertilizer Quality Supervision and Inspection Center (Beijing), Testing Centre of China Agriculture Academy of Science. They will formally issue new official fertilizer certificate in February 2008, replacing the previous Temporary Amino Acid Leaf Fertilizer Registration Certificate.

Mr. Wei Li, Board Chairman and CEO of Kiwa, stated: "Kiwa has always attached importance to the environmental influence of its products. We are pleased that these tests also confirm the economic benefits of using Kiwa's fertilizer products. We hope the promulgation of the test results and the achievement of earning the new official fertilizer certificate can give our customers a better understanding of the positive benefits of switching to and cause them to purchase Kiwa's products."

ABOUT KIWA BIO-TECH PRODUCTS GROUP CORPORATION

The Company develops, manufactures, distributes and markets innovative, cost-effective, and environmentally safe bio-technological products for agricultural and natural resources and environmental conservation. The Company's products are designed to enhance the quality of human life by increasing the value, quality and productivity of crops and decreasing the negative environmental impact of chemicals and other wastes. For more information about the Company, please review documents filed with the SEC (http://www.sec.gov) or visit the Company's website at http://www.kiwabiotech.com.

This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any such forward-looking statements involve risk and uncertainties that could cause actual results to differ materially from any future results described by the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward- looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.

For more information, please contact:

Kiwa Bio-Tech Products Group Corporation

Yvonne Wang

Tel: +1-626-715-5855

Email: kiwabiotech@gmail.com

Robert Schechter

Equity Communications

Tel: +1-212-499-6809

Email: ir4kiwa@hotmail.com


'/>"/>
SOURCE Kiwa Bio-Tech Products Group Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Discas, Inc. Sells Shares to SNX Organic Fertilizers, Inc.
2. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R)
3. Roche to Nominate Independent Directors for Election at Ventanas 2008 Annual Stockholders Meeting
4. Mindray Announces Appointment of Dr. Jixun Lin as Independent Director
5. InterCure and Mashco Announce Launch into Independent Pharmacies in the United Kingdom
6. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
7. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
8. Three Studies by Independent Scientists Highlighting Pressure Cycling Technology (PCT) to be Presented this Week at the British Mass Spectrometry Societys 29th Annual Meeting
9. ANX-514 Reduces Hypersensitivity Reactions Without Impacting Pharmacokinetics or Antitumor Activity in Preclinical Tests
10. Glycominds and Fox Chase Cancer Center Announce a Collaboration to Discover New Cancer Detection Diagnostic Tests
11. Researchers underscore limitations of genetic ancestry tests
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... 2016 , ... In anticipation of AxioMed’s exclusive cleanroom manufacturing ... President, Jake Lubinski will be traveling to Switzerland from December 5-10. Mr. Lubinski ... and Zurich to discuss the benefits of a viscoelastic disc. AxioMed received CE ...
(Date:12/2/2016)... Dec. 2, 2016  The Multiple Myeloma Research Foundation ... MMRF CoMMpass Study SM —the largest and most comprehensive ... in multiple myeloma—will be presented at the 58 th ... Exposition in San Diego from ... treatment strategies, as well as identify pathways and targets ...
(Date:12/2/2016)... ANGELES , Dec. 2, 2016 CytRx ... and development company specializing in oncology, today announced the ... noted sarcoma surgeon, industry consultant, and private healthcare investor, ... is a healthcare leader with clinical and strategic experience ... , CytRx,s Chairman and CEO. "As one of the ...
(Date:12/2/2016)... ... December 01, 2016 , ... ACEA Biosciences, Inc. announced today ... clinical trials for AC0010 at the World Conference on Lung Cancer 2016, taking place ... on the phase I/II clinical trials for AC0010 in patients with advanced non-small cell ...
Breaking Biology Technology:
(Date:11/22/2016)... , November 22, 2016 According to the ... IRIS, Palm Print, Face, Vein, Signature, Voice), Multi-Factor), Component (Hardware and Software), ... published by MarketsandMarkets, the market is expected to grow from USD 10.74 ... CAGR of 16.79% between 2016 and 2022. ... ...
(Date:11/17/2016)... Global Market Watch: Primarily supported by ownership types; ... Academics) market is to witness a value of US$37.1 billion ... Compounded Annual Growth Rate (CAGR) of 10.75% is foreseen from ... 2014-2020. North America is not way ... Europe at 9.56% respectively. Report Focus: ...
(Date:11/15/2016)... , Nov 15, 2016 Research and Markets ... Forecast to 2021" report to their offering. ... ... 16.18 Billion by 2021 from USD 6.21 Billion in 2016, growing ... Growth of the bioinformatics market is driven by the growing ...
Breaking Biology News(10 mins):